Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
1. Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as
determined by respective institutional standards, and will be based on medical
2. Brain metastasis diagnosis made between January 2006 - December 2008.
1. Women who have another primary cancer diagnosed between the time of breast cancer
diagnosis and brain metastasis..
2. Patient has leptomeningeal metastases only without parenchymal brain involvement
(since this pattern of the disease requires a different treatment approach.)
Type of Study:
Observational Model: Cohort, Time Perspective: Retrospective
To describe the treatment pattern of brain metastasis in ErbB2 over-expressing breast cancer in Asia Pacific countries.
Outcome Time Frame:
Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period
GSK Clinical Trials
United Kingdom: GSK Observational Study
- Breast Cancer
- ErbB2+ breast cancer
- ErbB2 treatment
- brain metastases
- Breast Neoplasms